Apixaban — Drug Intelligence | 50 EU Trials

Filter these 50 trials by condition, phase, country and more.

Open in Search →

50 Registered trials

26 Recruiting

18 Completed trials

41 Sponsors

26 Countries

Phase III

Phase IV

Phase III: 20 Phase II/III: 3 Phase II: 4 Phase III/IV: 1 Phase IV: 19 Other: 3

Oversight events:

2 serious breaches 13 temporary halts 1 urgent safety measure 2 unexpected events 5 corrective measures across 5 trials

View oversight register →

Indications tested

Atrial fibrillation 6 Chronic coronary syndrome 1 Intracardiac thrombus 1 Acute coronary syndrome 1 Cerebrovascular accident prophylaxis 1 Epstein-Barr virus associated lymphoma 1 Non-cirrhotic portal hypertension 1 Aortic valve stenosis 1 Diffuse large B-cell lymphoma 1 Neurosurgery 1 Aortic stenosis 1 Cerebral haemorrhage 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Saint Etienne 3 Oslo University Hospital HF 3 Regeneron Pharmaceuticals Inc. 3 Assistance Publique Hopitaux De Paris 2 Celgene Corp. 2 Centre Hospitalier Universitaire De Nantes 2 Hamilton Health Sciences Corporation 2 HUS-Yhtymae 2 Academisch Ziekenhuis Leiden 1 Academisch Ziekenhuis Maastricht 1 Alter Farmacia S.A. 1 Amsterdam UMC Stichting 1

All trials

50 total

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas… Pending

2024-515362-13-00 Phase II/III 1 country Centre Hospitalier Regional Et Universitaire De Brest
MidregiOnal proatrial natriuretic peptide to guide SEcondary Stroke prevention: The MOSES-study Pending

2024-517600-11-01 Phase III 2 countries Universitaetsspital Basel
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants with Solid and Hematologic Cancers Pending

2024-519299-16-00 Phase III 2 countries Regeneron Pharmaceuticals Inc.
Weight-loss Effects aNd absorption of Direct oral anticoagulants in roux-en-Y gastric bypass patients: a prospective study (WENDY) Pending

2024-519737-30-00 Phase IV 1 country Amsterdam UMC Stichting
Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES s… Pending

2025-520954-12-00 Phase IV 1 country Centre Hospitalier Universite De Laval
Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patient - PEACE Pending

2025-524110-28-00 Phase IV 1 country Region Hovedstaden
DIAMOND Study - DIrect oral anticoagulant for Antithrombotic Management Of aortic bioprothesis implanted patients for valvular heart Disease… Recruiting

2024-516643-64-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Assessing the Efficacy of a Single Measurement and Adjustment Strategy for DOACs in Frail Older Patients. Recruiting

2025-521362-10-00 Phase III/IV 1 country Academisch Ziekenhuis Maastricht
REGN7508 versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults. Recruiting

2025-520478-20-00 Phase III 6 countries Regeneron Pharmaceuticals Inc.
Restarting Early versus Later Anticoagulation for Chronic Subdural Hematoma with Atrial Fibrillation (RELACS) Recruiting

2025-521179-29-00 Phase II/III 2 countries HUS-Yhtymae
Comparison of the effects of prophylactic administration of Apixaban on thrombin generation in patients with de novo multiple myeloma and pa… Recruiting

2024-515329-27-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
Anticoagulation with apixaban in venous malformations Recruiting

2024-511930-11-00 Phase II 1 country Oslo University Hospital HF
RandomizEd compariSOn of apixaban versus warfarin in patients with Left VEntricular thrombus after Acute Myocardial Infarction (RESOLVE-AMI)… Recruiting

2024-514416-28-00 Phase IV 2 countries Karolinska Institutet
Thrombolysis in Factor Xa-inhibitors Trial (SIFT) Recruiting

2023-509907-34-01 Phase III 3 countries Oslo University Hospital HF
Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non valvular atrial fibrillation: a randomized controll… Recruiting

2023-507544-37-00 Phase III 1 country Centre Hospitalier Universitaire De Caen Normandie
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 Phase III 7 countries Insel Gruppe AG
Continuing Anticoagulants and Antiplatelets in Cold snare Polypectomy. Recruiting

2024-511265-11-01 Phase IV 1 country Fundacion Instituto De Investigacion Sanitaria Aragon
The Direct Oral Anticoagulation versus Vitamin K Antagonist after Cardiac Surgery (DANCE) Trial Recruiting

2023-504504-28-00 Phase III 1 country Hamilton Health Sciences Corporation
DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t… Recruiting

2023-510186-98-00 Phase IV 1 country Academisch Ziekenhuis Leiden
Short-term interruption versus continuous anticoagulation in colorectal polypectomy. A randomized multicenter investigator-initiated non-inf… Recruiting

2024-512194-27-01 Phase IV 1 country Hospital Universitario Ramon Y Cajal
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial Recruiting

2023-508147-43-00 Phase IV 1 country HUS-yhtymae
Can patients with atrial fibrillation discontinue anticoagulant therapy after cardiac surgery: The ATLAAC trial Recruiting

2022-502986-92-00 Phase IV 2 countries Odense University Hospital
Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress Recruiting

2023-509142-35-00 Phase IV 10 countries Hamilton Health Sciences Corporation
Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n… Recruiting

2023-504637-42-01 Phase IV 5 countries St Antonius Hospital

Showing 1–24 of 50 trials

← All drugs A–Z